They found that younger age, lack of extracranial metastases, better Karnofsky performance status score, fewer melanoma brain metastases, as well as treatment with BRAF inhibitors, anti-PD1/CTLA4 therapies, or cytokine therapy were significantly associated with improved overall survival (67). Here, PDCD1 is linked to melanoma.